Pharmacological studies on Elaeagnus angustifolia L. tinctures and extracts. Note 2. Experimental research about the flowers tincture antitumoral activity

Archives of the Balkan Medical Union

Volumn 43, Issue 2, 2008, Pages 107-112

  Bucur, Laura ^a,d   Taralunga Gh ^a,b   Istudor, Viorica ^c   Badea, Victoria ^a  

^a OVIDIUS UNIVERSITY   (Romania)

^b Medico Military Scientifical Research Center   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d 34 ^*  (Romania)

Author keywords

Antitumoral activity; Elaeagnus angustifolia L.; Flowers tincture

Indexed keywords

CYCLOPHOSPHAMIDE; ELAEAGNUS ANGUSTIFOLIA EXTRACT; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER MORTALITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG SCREENING; ELAEAGNUS ANGUSTIFOLIA; FEMALE; FLOWER; HUMAN; HUMAN CELL; IN VIVO STUDY; INOCULATION; LATENT PERIOD; MALE; MEDICINAL PLANT; NONHUMAN; RAT; SURVIVAL TIME; TINCTURE;

EID: 47949088781     PISSN: 15849244     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ciulei I. - Unele progrese în domeniul substanţelor naturale antineoplazice, Medicina modern?, 1996, 3 (2), 88-91.
2. Chu Y.F., Sun J., Wu X., et colab. - Antioxidant and antiploriferative activities of common vegetables, J. Agric. Food Chem., 2002, 50, 6910-6916.
3. Hertog M.G.L., Kromhout D., Aravanis C. - Havonoids intake and long-term risk of coronary heart disease and cancer in the seven countries, Study. Arch. Int. Med., 1995, 155, 381-386.
4. Sayyah M. - Evaluation of cytotoxic effects of Elaeagnus angustifolia L. extracts on the different types of human cancer cell lines, Grant nr. 188, Institut Pasteur of Iran.
5. Bucur L., Tarǎlungǎ Gh., Istudor V., Cǎsǎ ndroiu B. - Pharmacological studies on Elaeagnus angustifolia L. tinctures and extracts. Note 1. Single dose toxicity study of extracts.
6. Rusu V. şi colab. - Dicţionar medical, Editura Medicalǎ, Bucureşti, 2001, p. 173, 177.
7. Savini L., Chiasserini L., Travagli V., Pellerana C., Novellino E., et colab. - New -(N)-heterocyclic hydrazones: evaluation of anticancer, anti-HIV and antimicrobial activity, European J. Med. Chem., 2004, 39 (2), 113-122.
8. *** Norme şi protocoale analitice, farmacotoxicologice şi clinice referitoare la testarea medicamentelor - Ministerului Sǎnǎtǎţii Publice şi Agenţiei Naţionale a Medicamentului
9. Schiavoni G., Mattei A. şi colab. - Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice; implications for strategies of chemoimmunotherapy of cancer, Blood, 2000, 95 (6), 2024-2030.
10. Ichikawa T. şi colab. - Intraneoplastic polymer-based delivery of Cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector, Cancer Research, 2001, 61, 864-868.
11. Cristea A. - Tratat de farmacologie, ediţia I, Editura Medicalǎ, Bucureşti, 2005, p. 472.
12. th edition, Pergamont Press, New-York, 1990.
13. Popa L. - Elemente de metodologia cercetǎrii ştiinţ ifice în domeniul farmaceutic, ediţia a II-a revizuitǎ şi adǎugitǎ, Editura Printech, 2005, p. 165-200.
14. *** Farmacopeea Românǎ Ediţia a X-a, Editura Medicalǎ, Bucureşti, 1993, p. 1124-1162.
15. Radu G.L. - Tehnici experimentale în bioanalizǎ, Editura Printech, Bucureşti, 2004, p. 55.